BIOGEN INC. (BIIB) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-05

Key Insights

Adam Keeney, Head of Corporate Development at Biogen, acquired 939 shares through restricted stock unit (RSU) vesting on May 1, 2026, with a grant date of May 1, 2023, vesting in three equal annual installments.
Keeney simultaneously sold 455 shares at $187.06 per share, generating approximately $85,000 in proceeds, likely to cover tax obligations from the RSU vesting.
Following these transactions, Keeney maintains direct beneficial ownership of 6,365 common shares, indicating continued confidence in the company despite partial share disposal.
The RSU vesting structure and modest insider selling pattern suggests routine equity compensation execution rather than a significant bullish or bearish signal about company prospects.

Want the newest filings?

This analysis covers the filing from 2026-05-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-03

Insider Sean Godbout, the Chief Accounting Officer, exercised 181 restricted stock units and sold 54 shares of Biogen stock on April 1, 2026.
Godbout's net ownership decreased from 1,395.6667 shares to 1,341.6667 shares as a result of this transaction.
The restricted stock units vested in three equal yearly installments beginning on the first anniversary of the grant date of April 1, 2025.

Filed: 2026-02-10

Nicole Murphy, the Head of Pharmaceutical Operations and Technology at Biogen, has exercised 8,725 restricted stock units and sold 3,339 shares on February 6, 2026.
The transactions indicate that Murphy is partially liquidating her equity holdings in Biogen, which could signal a change in her confidence or outlook on the company's prospects.
The insider selling activity, combined with the vesting and exercise of stock-based compensation, is worth monitoring as it may provide insights into the company's performance and management's perspective.

Filed: 2026-02-10

The reporting person, Christopher A. Viehbacher, acquired 9,008 shares of common stock through the vesting of restricted stock units, and subsequently sold 4,356 shares to cover tax withholding obligations.
Viehbacher also acquired an additional 15,453 shares through the vesting of restricted stock units, and sold 6,624 shares to cover tax withholding.
After these transactions, Viehbacher's direct beneficial ownership of Biogen's common stock increased from 25,451 shares to 29,924 shares.

Filed: 2026-02-10

Priya Singhal, the Head of Development at Biogen, exercised restricted stock units and sold a portion of the acquired shares, which suggests potential insider confidence in the company's future prospects.
The timing of Singhal's transactions, occurring in early February 2026, may provide insights into Biogen's near-term outlook and potential business developments.
The relatively large amount of shares involved in this transaction, totaling over 6,900 shares, indicates a significant change in Singhal's beneficial ownership position in the company.

Filed: 2026-02-10

Robin Kramer, the Chief Financial Officer of Biogen, has acquired 5,003 shares of the company's common stock through the vesting of restricted stock units on February 6, 2026.
Kramer has also sold 1,543 shares to cover tax withholding obligations, leaving him with a net increase of 3,460 shares in his direct ownership of Biogen stock.
The insider transactions suggest Kramer's continued confidence in Biogen's prospects, as he retains a significant stake of over 11,400 shares in the company.

Filed: 2026-02-10

Adam Keeney, the Head of Corporate Development at Biogen, exercised 5,080 restricted stock units and sold 1,583 shares to cover tax withholding obligations.
Keeney's net ownership increased from 4,186 shares to 5,881 shares, indicating he is holding onto a significant portion of his equity compensation.
The timing and magnitude of these transactions suggest Keeney remains confident in Biogen's long-term prospects and is aligning his personal financial interests with those of the company and its shareholders.

Filed: 2026-02-10

Rachid Izzar, the Head of Global Product Strategy at Biogen, has exercised 6,889 stock options and restricted stock units, suggesting confidence in the company's future.
Izzar has sold 2,038 shares to cover tax withholding obligations, indicating he is retaining a significant portion of the shares received.
The vesting of the stock options and restricted stock units is staggered over multiple years, providing long-term incentives and alignment with shareholders.

Filed: 2026-02-10

Insider Dr. Jane Grogan, Head of Research at Biogen, has exercised restricted stock units (RSUs) to acquire 3,258 shares of Biogen common stock, indicating confidence in the company's future.
Dr. Grogan has also sold a portion of her shares, likely for tax purposes, retaining a significant stake of 4,058 shares in the company.
The vesting schedule of the RSUs suggests Biogen is incentivizing its research leadership through long-term equity compensation, aligning their interests with shareholders.

Filed: 2026-02-10

Gregory Ginger, an EVP at Biogen, exercised 7,183 stock options and restricted stock units in a series of transactions on February 6, 2026.
The total number of Biogen shares beneficially owned by Ginger increased from 19,399.7673 to 23,490.7673 as a result of these transactions.
Ginger sold a portion of the acquired shares to cover tax withholding obligations, indicating some liquidity needs, but overall maintained a significant equity stake in the company.

Filed: 2026-02-10

The reporting person, Sean Godbout, is the Chief Accounting Officer of Biogen Inc. and has acquired a significant number of shares through the vesting of restricted stock units.
Godbout has disposed of a portion of the shares acquired through the vesting, likely for tax purposes, but still maintains a substantial direct ownership position in the company.
The restricted stock unit grants appear to be on a regular annual schedule, providing Godbout with long-term incentive compensation aligned with shareholder interests.

Filed: 2026-02-10

The reporting person, Susan H. Alexander, who is the EVP and Chief Legal Officer of Biogen Inc. (BIIB), acquired a total of 9,046 shares of BIIB common stock through the vesting of restricted stock units (RSUs) on 02/06/2026.
The reporting person disposed of 3,504 shares of BIIB common stock to cover tax withholding obligations related to the vesting of the RSUs, leaving her with a total of 41,807 direct shares and 20,082 indirect shares held in a trust.
The insider transactions suggest the reporting person's continued commitment to and confidence in Biogen's long-term growth and performance, as evidenced by the vesting and retention of a significant portion of the awarded RSUs.

Other reports for BIOGEN INC.

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.